Key facts
- It has raised $16.7M across 1 recorded rounds; the latest was Early Stage VC ($15.0M) in Jun 2024.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, U.S. Department of Energy, National Institutes of Health, United States Department of Agriculture — 16 tracked in total.
- Primrose Bio has filed 1 Form D with the SEC, most recently Jul 2024 ($15.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Primrose Bio
Funding rounds
1 roundsAbout Primrose Bio
Developer of constructive biology technologies designed to accelerate the evolution of efficient enzymes and microbes. The company uses powerful technology to advance bio-production and to create efficient manufacturing systems for high-value molecules and materials, enabling the healthcare industry to transition towards a diverse and integrated bio-economy.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 53
- Website
- primrosebio.com/
- Ownership
- Privately Held (backing)
Primrose Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primrose Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primrose Bio in its N-PORT filings yet. We sweep new filings monthly.